Table 1 Patient characteristics and treatment options, all patients, 1983-2007
Variable | Subgroup | n = 503 | % |
|---|---|---|---|
Gender | M | 400 | 79.5 |
W | 103 | 20.5 | |
Age | < 50 | 73 | 14.5 |
50-59 | 158 | 31.4 | |
60-69 | 151 | 30 | |
70+ | 121 | 24.1 | |
median y | 61 | ||
range y | 35-91 | ||
Histology | AC | 95 | 18.9 |
SCC | 395 | 78.5 | |
unknown | 13 | 2.6 | |
Grading | G1+2 | 217 | 43.2 |
G3+4 | 262 | 52.1 | |
unknown | 14 | 2.8 | |
T | T1+2 | 114 | 22.7 |
T3 | 259 | 51.5 | |
T4 | 90 | 17.9 | |
unknown | 39 | 7.8 | |
N | N0 | 203 | 40.4 |
N1 | 253 | 50.3 | |
unknown | 47 | 9.3 | |
M | M1 | 113 | 22.5 |
unknown | 28 | 5.6 | |
UICC | I-IIB | 190 | 37.8 |
III+IV | 281 | 55.9 | |
unknown | 32 | 6.4 | |
Localisation | cervical | 23 | 4.6 |
upper thoracic | 114 | 22.7 | |
mid thoracic | 147 | 29.2 | |
lower thoracic | 201 | 40 | |
unknown | 18 | 3.6 | |
Therapy | prim. | 353 | 70.2 |
RT/RCT | 125/227 | (35.4/64.3) | |
adjuvant | 51 | 10.1 | |
RT/RCT | 20/28 | (39.2/54.9) | |
neoadj. | 83 | 16.5 | |
RT/RCT | 17/63 | (20.5/75.9) | |
unknown | 16 | 3.2 | |
RT | 172 | 34.2 | |
RCT | 322 | 64 | |
unknown | 9 | 1.8 | |
Chemotherapy | 322 | 100 | |
5FU+MMC | 213 | 66.1 | |
5FU+Cisplatin | 22 | 6.8 | |
5FU | 61 | 18.9 | |
cisplatin | 8 | 2.5 | |
unknown | 18 | 5.6 | |
RT dose in Gy | ≤50 | 151 | 30 |
> 50-≤54 | 72 | 14.3 | |
≥54- < 60 | 85 | 16.9 | |
≥60 | 168 | 33.7 | |
unknown | 17 | 3.4 | |
2D/3Dplanning | 2D | 289 | 57.5 |
3D | 180 | 35.8 | |
AL only | 7 | 1.4 |